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Abstract Homozygous complement C4B deficiency is described in a Southern European young
female patient with Membranoproliferative Glomerulonephritis (MPGN) type III characterized by
renal biopsies with strong complement C4 and IgG deposits. Low C4 levels were independent of
clinical evolution or type of immunosuppression and were found in three other family members
without renal disease or infections. HLA typing revealed that the patient has homozygous A*02,
Cw*06, B*50 at the class I region, and DRB1*08 and DQB1*03 at the class II region. Genotypic and
phenotypic studies demonstrated that the patient has homozygous monomodular RCCX in the
HLA class III region, with single long C4A genes coding for C4A3 and complete C4B deficiency. Her
father, mother, son and niece have heterozygous C4B deficiency. The patient's deceased brother
had a history of Henoch–Schönlein Purpura (HSP), an immune complex-mediated proliferative
glomerulonephritis. These findings challenge the putative pathophysiological roles of C4A and
C4B and underscore the need to perform functional assays, C4 allotyping and genotyping on
patients with persistently low serum levels of a classical pathway complement component and
glomerulopathy associated with immune deposits.
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The complement system is an essential element of the innate
immune system [1]. The lack of any complement component
may severely disturb host defenses. Complement componentvedC4 plays a central role in classical and lectin complement
activation pathways. C4 has two isotypic forms, C4A and C4B,
encoded by loci in the MHC class III region on chromosome 6.
The number of C4 genes varies between two and eight in a
diploid genome among different individuals [2]. A C4 gene
duplication is always concurrent with its neighboring genes
RP at the 5′ region and CYP21 and TNX at the 3′ region [3].
This unit is known as an RCCX module (Fig. 1). Low C4A and
C4B copy-numbers (i.e., 0 or 1 copy) have a combined
frequency of 31.6% and are associated with a variety of
autoimmune or infectious diseases [4]. A complete.
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strongly associated with impaired immune complex clear-
ance and systemic lupus erythematous (SLE) [5]. On the
other hand, homozygous complement C4B deficiency has a
frequency of 3% in the American Caucasian population [6].
There have been a few case reports regarding homozygous
C4B deficiency and non-SLE glomerulonephritis [7–11].
Idiopathic MPGN represents only 6.4–7.3% of all primary
glomerulopathies [12–15] and only 0.4% of all patients
receive renal replacement therapy (USRDS). The renal
outcome is poor, with a 10-year survival of 32–40%, and a
remission rate of 5.0–7.6% [13,16]. MPGN type III is a rare
renal disease of unknown cause, usually sporadic, represent-
ing less than 1% of glomerulonephritis in URSD registry data
[17]. There are a few cases with MPGN and C4 deficiency
reported in the literature [18–21] and even fewer cases
associated with C4B*Q0 [19,20].
Here we report a family with two siblings who were
inflicted with proliferative glomerulonephritis, one of whom
had confirmed complete C4B-deficiency. Four family mem-
bers had heterozygous C4B deficiency. The dosage of the C4A
and C4B genes, three other constituent genes of the RCCX
modules, and C4 protein phenotypes were investigated. The
clinical presentation of MPGN type III for this C4B deficient
patient is described.
Materials and methods
Blood donors
Informed consents were obtained from blood donors accord-
ing to IRB-approved protocol. Peripheral blood in EDTA-tubes
was used for isolation of genomic DNA and plasma samples,
as described [2].
Real-time PCR assays of C4 gene copy-numbers
A TaqMan-based quantitative real-time PCR strategy was
applied to determine the gene copy-numbers of total C4, C4A
and C4B in DNA samples rapidly, as described [22].
Southern blot analysis
Genomic DNA samples were digested with TaqI restriction
enzyme, resolved by agarose gel electrophoresis, Southern
blotted, hybridized with probes that annealed to genomic
regions for RP and C4, CYP21, and 3′ region of TNX. B. PshAI–
PvuII RFLP for C4A and C4B. Genomic DNA samples were
digested with PshAI that differentiates between the C4A and
C4B isotypic sequences, and with PvuII to improve separation
of genomic DNA fragments specific for C4A and C4B. After
agarose gel electrophoresis and Southern blotting to nylon
membrane, the membrane was hybridized to a C4d specific
probe labeled by 32P-dCTP [2].
Allotyping of C4 proteins
EDTA-plasma samples were digested with neuraminidase and
carboxylpeptidase B, resolved with high-voltage agarose
gel electrophoresis, immunofixed with goat anti-human C4antisera, blotted to remove diffusible proteins and stained
[2,23].Results
Index case
A 28-year old white female first presented with anasarca
because of nephrotic syndrome. She was hypertensive; urine
protein excretion was 7 g/d and serum albumin 1.7 g/dL,
associated with microscopic hematuria, red cell casts and
normal renal function. Serum C3 protein concentration was
normal, C4 level was persistently low (5–7 mg/dL; normal
range 17.4–52.2 mg/dL), IgG was low (247 mg/dL; normal
range 690–1400 mg/dL). Autoantibodies (antinuclear, anti-
DNA, anti-Sm, anti-RNP, anti-Ro/SSA, and anticardiolipin),
MPO-ANCA and cryoglobulins were absent. Bacterial cul-
tures, and viral (HIV, HCV, and HBV) serology were negative.
She did not meet diagnostic criteria for SLE. Light microscopy
of kidney biopsy showed a probable type III MPGN with
extensive deposits (Fig. 2A). The most prominent anomaly
was a general thickening of the capillary walls which
sometimes assumed a broad glassy eosinophilic appearance
and reduced capillary lumens. Hyperlobularity was not
apparent. Inflammatory cells were not conspicuous and
there were neither tuft necrosis nor crescents. Interstitial
fibrosis or tubular atrophy was mild. The presence of
frequent double contours in most loops but a lack of spikes
was demonstrated with Jones's silver stain. Any existing
deposits within the loops were not stained with silver
(Fig. 2B). Immunofluorescence (IF) showed intense (3+) C4
and IgG, moderate (2+) C1 and IgM, and weak (1+) IgA and C3,
globally distributed large confluent granular deposits, form-
ing a pseudolinear pattern within capillary walls (Fig. 2C).
The more intense and larger deposits had globular or
semilunar profiles. There was some granular mesangial
staining with weaker intensity. These IF results suggested
immune complex deposition. Electron microscopy was
consistent with a Strife and Anders type of type III MPGN
[24,25]. In most capillaries the profile of the normal lamina
densa was not visible. In its place were numerous moderately
dense deposits, usually uniformly textured aggregates of
finely granular material, sometimes less well-defined irreg-
ular aggregates. These deposits predominated on the
epithelial side, but many extended from epithelium to
endothelium. Mesangial deposits were noted more in the
paramesangial region. A thin reactive type continuous
lamina densa closely hugged and separated the dense
deposits from the extensively thinned and effaced podocytes
and, discontinuously, from endothelial cells. These inner and
outer dense laminas corresponded to the double contours.
Mesangial interposition into the capillary was confirmed.
Spikes were not identified. In the glomerulus with a few less
affected loops the lamina densa was single and normal;
scattered fairly large and uniform subendothelial dense
deposits were occasionally observed on these loops. No
tubuloreticular structures were noted. (Fig. 2D). Lupus
nephritis was considered to be the most likely differential
diagnosis.
Therapy was started with methylprednisolone pulses,
followed by oral prednisolone (1 mg/kg) and six 1 g
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Figure 2 First renal biopsy of the patient: Light microscopy (A) Silver stain (B), immunofluorescence (C), electromicroscopy (D). 2A
Detail of the diffuse glomerulonephritis showing prominent generalized thickening of the capillary walls, sometimes with a broad
glassy eosinophilic appearance (1, 2). There was slight to moderate increase in mesangial cells and expansion of the mesangial regions.
Capillary lumina appear generally reduced. H+E. 2B. Within the thickened capillary walls the basement membrane appears irregular,
interrupted or vacuolated (1, 3, 4). There are also several double contours some of which with a fairly thin outer contour (2, 3, 5). Any
existing deposits within the wall appeared unstained with silver (5). One capillary wall has relatively normal wall (6). Mesangial matrix
was mildly increased (5). Jones's silver. 2C Intense confluent granular deposits of C4 with pseudolinear pattern globally distributed
within the capillary walls and less intense mesangial staining. Large intense globular or semilunar collections in the wall were also
seen. 2D Low magnification E.M: Capillaries (C1, C2) with endothelium (End1 to End3), Bowman's space and visceral epithelium (E). In
the thickened and deformed wall there are large, numerous moderately dense deposits (D1 to D5) more concentrated towards the
subepithelial zone, but also extending through the whole wall (D2). Generally the dense deposits have uniform texture (D1 to D3) but
some show complex irregular texture which includes less dense vesicular profiles, small clear spaces and groups of convoluted fine
plasma membrane like structures (D4, D5). Generally there was no definition of the normal lamina densa of the basement membrane.
Reactive type continuous thin lamina densa was seen along the epithelial side effectively separating the dense deposits from the
podocytes (between black arrows). Clear cut formation of spikes was not seen. Reactive thin lamina densa on the endothelial side was
ill defined and discontinuous. Mesangial cell (Mes) interposition was represented by multiple small cytoplasmic processes (white
arrows) within the thickened capillary wall. There was severe thinning of podocytes and extensive effacement of foot processes.
Negative magnification 2500×.
169C4B deficiency and glomerulonephritisCyclophosphamide monthly pulses. After 16 weeks of ther-
apy the protein/creatinine urinary ratio (PCUR g/g) de-
creased below 0.6 and prednisone was tapered over eight
months. The patient was admitted at the eleven month of
follow-up. She had a marked increase of PCUR to 9, and was
eight weeks pregnant. Because of the risks for both patientFigure 1 The gene size and polygenic variations of human complem
region. A. Copy-number variation of RCCX modules; B. Exon–intr
endogenous virus inserted into intron 9 of long C4 genes; C. Commo
(in kb) for each haplotype (modified from ref. [50]).and fetus, a therapeutic abortion was performed and the
urine protein excretion declined. For the next 9 months the
patient remained without immunosuppressants. The PCUR
again increased to almost 5 and therapy with Mycophenolate
Mophetil (MMF) 1 g twice-a-day plus prednisolone (PRED)
20 mg every other day, was begun at month 18. There was aent C4 and RP-C4-CYP21-TNX (RCCX modules) in the MHC class III
on structure and size variation of C4 gene; HERV-K(C4) is an
n RCCX haplotypes and diagnostic TaqI restriction fragment size
170 K. Soto et al.quick response, but after six months the PCUR rose
progressively to 7, probably related to non-compliance, as
admitted by the patient. In the following year and without
immunosuppression the PCUR decreased to below 4 and
increased again to 8.5 (Fig. 3). A second renal biopsy was
performed at the 41st month of follow-up, which confirmed
MPGN type III diagnosis, but with fewer immune deposits and
without signs of chronicity (Figs. 4 A–C). The glomerular
capsule appeared marginally thicker than that observed in
the first biopsy. Immunofluorescence showed, in general,
weaker reactions for all immune proteins. However there
were still extensive moderate (2+) pseudolinear IgG and C4
and slight (1+) C1 and IgM deposits, all predominating within
the capillary walls. Large globular or semilunar collections
similar to those of the first biopsy remained present. IgA and
C3 appeared much reduced, but there were strong segmental
capsular and hilar deposits of C3. It was assumed that the
evolution was related to the immunosuppressant therapy.
MMF/PRED was re-started. During the six years of follow-up
the patient received three cycles of MMF/PRED, serum C4
levels remained depressed persistently and the serum
albumin and PCUR were never normalized. Renal function
remained normal. The patient was under ACE inhibitor
treatment from the start.Family study
The patient's brother died on dialysis at age 28. A diagnosis of
Henoch–Schonlein purpura (HSP) with proliferative glomer-
ulonephritis was made at age 14. Neither the biopsy nor C4
protein levels were available for review.
Clinical and laboratory testing of four direct relatives of
the patient revealed a normal urinalysis and renal function.
Her father, son and niece (sister's daughter) had low C4 levels
without disease. Therefore, we proceeded to a genetic
analysis and protein allotyping of complement C4.Figure 3 Time course of proteinuria in response to different thera
PRED: prednisolone initially 1 mg/kg four month and then taper
angiotensin converting enzyme inhibitors RPC: ratio of urinary prote
component C4 mg/dL (normal range 17.4–52.2).Genotypic and phenotypic studies of
complement C4
The results of the family study for complement C4 haplotypes
are shown in Fig. 5. Genomic DNA samples were isolated from
peripheral bloodmononuclear cells. A TaqMan-based real-time
PCR strategy [22] was initially applied to determine the copy-
number ofC4A andC4B in each subject. The index patient has a
total of two C4 genes in her diploid genome: two copies of C4A
but no C4B. The father and the niece each has three copies of
C4 genes: two copies of C4A and one copy of C4B.
We further investigated the RP-C4-CYP21-TNX (RCCX)
modular variation by genomic Southern blot analyses of TaqI
and PshAI–PvuII restriction fragment length polymorphisms
(RFLP) and probed for genes in the RCCX module [2]. TaqI
RFLP identified numbers of long and short C4 genes and RCCX
haplotypes. The index patient has homozygous, monomod-
ular RCCX (L/L) with single copies of long C4 genes, and
single copies of neighboring genes for steroid CYP21B and
tenascin TNXB (Fig. 5A). PshAI–PvuII RFLP showed that the
C4 genes present in the index patient were C4A genes, while
C4B genes were absent (Fig. 5B). Immunofixation using EDTA-
plasma revealed the presence of C4A3 allotype and complete
absence of C4B protein in the index case (Fig. 5C). The father
has bimodular-LL and monomodular-L RCCX (LL/L) haplo-
types with three copies of C4 genes: two C4A and one C4B.
The mother has a total of three C4 genes with bimodular-LS
and monomodular-L; two C4A and one C4B. The patient
inherited the monomodular-L haplotypes with C4A (but no
C4B) from each parent. Immunofixation of EDTA-plasma C4
showed that the mother has C4A3, C4A3 and C4B2 protein
allotypes, while the son has C4A3, C4A3 and C4B1 allotypes,
which are consistent with the genotypic data.
Complement C4 and the RCCX modules are located in the
class III region of the human major histocompatibility
complex, or the HLA. Thus, HLA typing of class I and class II
genes was performed for the patient and her five directpeutic approaches CF: Cyclophosphamide, 6 1 g monthly pulses
ing MMF: Mycophenolate Mophetil 0.5–1 g twice-a-day ACEI:
in/creatinine (g/g) Alb: serum albumin (g/dL) C4: Complement
Figure 4 Second Biopsy: silver stain LM (A), EM (B). 4A. The
basement membrane was generally irregular, sometimes inter-
rupted (1,2) and double contours were present (3). The
vacuolated or moth eaten profile of the walls, seen in the first
biopsy, was widespread and also present in the paramesangium.
Capillaries with normal single layer basement membrane were
not seen. The glomerular capsule appeared marginally thicker
than in the first biopsy. 4B. The walls of 2 capillaries with
endothelial cells (End1 and End2) contained several dense
deposits (examples D1 to D4). D1 appeared rarified and
surrounded by thin reactive basement membrane which
appeared well-defined and continuous in the subepithelium
(thin arrow) and discontinuous in the subendothelium. D2 made
direct contact with the podocyte. D3 had fairly uniform high
density and was also partly surrounded by subepithelial
basement membrane. There was a gap between podocyte
processes leaving D4 in direct contact with Bowman's space.
Mesangial cell cytoplasm (Mes) interposition was seen in the wall
near D4 and other deposits. Negative 6000×.
171C4B deficiency and glomerulonephritisfamily members to identify the haplotype associated with
C4B deficiency. The patient has homozygous HLA A*02,
Cw*06, and B*50 at the telomeric class I region, and DRB1*08
and DQB1*03 at the centromeric class II region. All other
family members were heterozygous with this haplotype
(Fig. 6).Discussion
MPGN type III is a rare, sporadic and progressive renal disease
of unknown etiology. The finding of immune complexes withcellular inflammatory infiltrate suggests an immune medi-
ated process. In some cases, a genetic basis of the diseases is
evident, particularly in families [26] with inherited defects
of the complement system [27–29]. Only a few cases have
been reported with C4 deficiency [18–21,30] and one with
isolated C4B deficiency [19].
Early in her disease presentation, the index patient was
treated as if she had lupus nephritis, although she did not
fulfill the diagnosis criteria for SLE clinically or serologically
[31]. The patient received three alternated cycles of
immunosuppression for about six years and spent almost
two years without medication. There was a significant
reduction of proteinuria during the treatment period but
complete remission was never achieved and C4 levels
remained depressed throughout the follow-up period.
The brother had reached an end-stage renal disease
because of a proliferative immune complex-mediated
glomerulonephritis with IgA deposits, and was diagnosed of
Henoch–Schonlein purpura (HSP). The histology of IgA
nephropathy and HSP is characterized by glomerular IgA,
IgG and C3 deposits mainly in the mesangium but also in the
capillary wall. Unfortunately, the brother's renal biopsy was
not available for review. It is unusual for two siblings to be
inflicted with immune complex-mediated glomerular inju-
ries. We speculate that this could be related to the presence
of C4B deficiency in the family. In this regard, the
coexistence of IgA nephropathy and MPGN in several
members of the same family had been reported previously,
and it was associated with specific C4 polymorphisms [32].
Complement abnormalities in patients with HSP nephritis
have previously been reported [7,11,33–35] and C4 defi-
ciency was suggested as a risk factor for HSP nephritis and
other immune complex glomerulonephritis, possibly due to a
defective clearance mechanism [36,37]. C4 null alleles are
common in HSP patients and the C4B*Q0 allele is thought to
increase the risk of developing HSP [33]. Other authors have
reported HSP patients with familiar C4 deficiency [30]. Low
C4 levels in three family members, genotyping and pheno-
typing of C4 revealed that our patient was homozygous for
C4B deficiency with HLA haplotype A*02-Cw*06-B*50-C4A3
(L)-DRB1*08-DQB1*03. Her parents each was heterozygous
with this haplotype, and had only one copy of C4B gene,
similar to the patient's son and niece. Phenotypically,
heterozygous deficiency of either C4A or C4B is a common
immune protein defect in all human populations as a
consequence of the high frequency of the MHC haplotypes
with C4 gene copy-number variations, although homozygous
deficiency is rarer [38]. In Caucasians, more than two-thirds
of the MHC haplotypes have two copies of C4 genes; the other
haplotypes mainly possess either one C4 or three copies of C4
genes. Each of these C4 genes may be long (L) or short (S).
The number of long or short C4A and C4B genes present in an
individual plays a role in determining the basal level of C4
proteins in the peripheral blood plasma. The index patient
has only single copy of long C4 gene coding for the C4A
protein on each of her chromosome 6, which is one of
the causes for persistently low levels of plasma C4. The
varying efficiencies of complement activation that result
from differential expression levels and protein polymorph-
isms of C4A and C4B may have a profound effect on an
individual's strengths in innate and adaptive immune
systems, and susceptibility to systemic autoimmune
Figure 5 Genotyping and phenotyping of complement C4. A. TaqI restriction fragment length polymorphism (RFLP) and Southern
blot analyses of RCCX modules. B. PshAI–PvuII RFLP for C4A and C4B. C. Immunofixation of C4A and C4B proteins. Abbreviations:
P, index patient; F, father; M, mother, S, son; N, niece; C, C1 and C2, three different healthy control subjects.
172 K. Soto et al.diseases. C4 null alleles represent relevant disease markers
and additive genetic risk factors for autoimmune phenomena
in multiple races [36]. Cumulative results from more than 35
different studies revealed that heterozygous and homozy-
gous deficiencies of C4A were present in 40–60% of SLE
patients among northern and central Europeans, Anglo-
Saxons, Caucasians in the US, Afro-Americans, Asian Chinese,
Koreans and Japanese [5]. Interestingly, Spanish, Mexican
and Australian Aborigine SLE patients had increased fre-
quencies of C4B deficiency instead of C4A deficiency [39,40].
It is possible that different racial and genetic backgrounds
could change the thresholds for the requirement of C4A or
C4B protein levels in immune tolerance and immune
regulation [4]. There is no information on the frequency ofC4B deficiency in SLE and lupus-like patients in the
Portuguese population. We speculate that the frequency
might be similar to that in the Spanish population [40].
While the coexistence of C4B deficiency and type III MPGN
could be coincidental, there are pathophysiological path-
ways that can explain the association. C4 deficiency is
frequently associated with immune complex disease [36].
C4B is important in the formation of the classical pathway
C3 covertase, leading to the assembly of the membrane-
attack complex against microbes [37]. A C4B deficiency
would adversely affect the efficiency and progression of the
complement activation, and possibly diminish the capacity of
phagocytosis and clearance of pathogenic immune com-
plexes, apoptotic and necrotic cells, predisposing an
Figure 6 Family tree with HLA and complement C4 genotypes. One of the patient's siblings was deceased and no genetic data was
available.
173C4B deficiency and glomerulonephritisindividual to developing immune complex-mediated diseases
such as HSP or MPGN. Human subjects with a genetic
predisposition to infection or an impaired protection against
autoimmunity would be vulnerable to immune complex
glomerulonephritis. In this regard, infection may be compli-
cated by MPGN or HSP/IgA nephropathy. Different reports
have showed an association between glomerulonephritis and
C4B deficiency in patients with SLE or Lupus-like disease
[10,20,37,41]. Tsuda et al. [19] also reported a MPGN-III
patient from Japan with null C4B and persistently low C4
levels. Interestingly, the patient's renal biopsy revealed
strong positive staining for C3 and weak staining for C4.
We further investigated the status of two other immune
effectors genes that exhibit gene copy-number variations
and play a role in renal diseases, which were complement
factor H-related genes CFHR3-R1 located at chromosome
1q32 [42,43], and immunoglobulin Fcγ-receptor FCGR3B
located at chromosome 1q23 [44], in our patient and direct
family members. Through genomic Southern blot analyses of
TaqI digested genomic DNA with gene-specific probes for
CFHR1, CFHR2, CFH3 and CFHR4, and for FCGR3B and
FCGR3A, we did not observe a deletion of CFHR3–CFHR1,
or low copy-number FCGR3B, in all six members of the family
(data not shown).
The clinical course of MPGN type III is not clear, long-term
kidney survival is poor, and there is little evidence for a
specific treatment to improve outcome. Reviews of immu-
nosuppression trials in adults did not reveal any significant
benefit [45–48]. The onset with nephrotic syndrome worsens
the prognosis. Lhotta [41] described a C4-deficient patient
with membranous nephritis who responded well to MMF
therapy. We therefore decided to use this option, bearing in
mind that MMF inhibits the proliferation of activated B and T
lymphocytes and antibody synthesis, and limits immune
complex deposition in the glomeruli [49]. We observed that
MMF reduced urinary protein excretion by almost 70%. The
treatment was well tolerated, without infections. Renal
function in our patient has remained normal during more
than 6 years of follow-up.Immunofluorescence staining for C4 is not a routine part
of renal biopsy evaluation in the USA. However, in this case,
it was the unusual pattern of very strong and widespread C4
capillary wall deposits observed on immunofluorescence that
suggested from the outset that we were faced with a rare
condition. This finding together with the persistent low C4
in the serum, absence of lupus or infection parameters
initiated the search for a possible familial defect. We suggest
that routine use of C4 staining could result in identification
of further similar cases.
C4B deficiencies have not been well-documented in (and
rarely associated with) MPGN-III. Measurement of C4 protein
levels may not detect C4A or C4B deficiencies; more
elaborate diagnostic tests, such as C4 protein allotyping
and genotyping, are required to identify complement C4
deficiencies in familial glomerulopathy. Our understanding
of the exact mechanisms by which complement abnormal-
ities lead to specific disease phenotypes is still poor. More in
depth analyses are required for a better understanding of the
pathogenesis and, thus, the development of specific
therapies.
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